Tango Therapeutics
About company:
Tango Therapeutics is using the principle of synthetic lethality to develop medicines for cancer patients. Synthetic lethality describes a situation where loss of two targets results in cell death, while loss of either one alone does not. Since some tumors already possess target loss, Tango is using their CRISPR-based functional genomics target discovery platform and analytic pipeline to identify novel synthetic lethal targets that can selectively kill tumor cells. Tango is applying this approach in two core areas: [1] tumor suppressor gene loss and [2] immune evasion. Once targets are identified, Tango screens for drugs that have therapeutic potential. Tango’s lead candidate, TNG908, is being evaluated in clinical trials for MTAP-deleted tumors.
Jobs:
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com